Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03160274 · ClinicalTrials.gov registry record
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
A clinical trial of Pheochromocytoma and Paraganglioma, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT03160274 is a study of Pheochromocytoma and Paraganglioma that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 2,000 participants, above the 377-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (431% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03160274, a study of Pheochromocytoma and Paraganglioma, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins.
Conditions Studied
Interventions
- GENETIC Genetic screening
Study Locations (1)
Texas
- University of Texas Health Science Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2005-10-19 |
| Est. Completion | 2030-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03160274
The ClinicalTrials.gov registry entry for NCT03160274 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 377-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (431% higher). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Pheochromocytoma appearing as the primary indexed condition, and to 1 intervention - of which Genetic screening is the first listed.
NCT03160274 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03160274 about?
NCT03160274 is a clinical study titled "Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions". Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The a...
What is the current status of trial NCT03160274?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2005-10-19. Estimated completion is 2030-12-31.
What conditions does trial NCT03160274 study?
This clinical trial studies the following conditions: Pheochromocytoma, Paraganglioma, Kidney Neoplasms, Thyroid Neoplasms, Other Cancer.
What interventions are being tested in trial NCT03160274?
The interventions under investigation include: Genetic screening (GENETIC).
Who is sponsoring clinical trial NCT03160274?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03160274 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pheochromocytoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
RECRUITING · Phase 1
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Diagnosis of Pheochromocytoma
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
RECRUITING · Phase 1
-
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.